CONDITION. I I’M A DIRECT SUPPORT PROFESSIONAL WITH THE ARC OF CARROLL COUNTY. BETHANY CHALMERS LOVES HELPING PEOPLE AND CONNECTING WITH OTHERS. BUT THOSE CONNECTIONS BECAME MORE CHALLENGING AFTER SHE ...

Tardive dyskinesia is a hyperkinetic movement disorder that causes faces to move involuntarily and abnormally. It is considered to be a drug-induced movement disorder. Movements often occur in the ...

Tardive Dyskinesia or TD is associated with certain prescription medications used to treat mental health or gastrointestinal conditions, and affects a broad range of people. It is characterized by ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription ...

Gray matter volume was compared among 3 groups, including healthy controls and those with schizophrenia with and without TD. Volume loss was greater in study participants with TD compared to controls ...

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive dyskinesia, ...

TRENTON, N.J. (AP) — U.S. regulators have approved the first drug for treating a neurological syndrome that causes uncontrollable body movements that can also interfere with speech, swallowing and ...

TRENTON, N.J. --U.S. regulators have approved the first drug for treating a neurological syndrome that causes uncontrollable body movements that can also interfere with speech, swallowing and ...

Tardive dyskinesia is a medication-induced movement disorder. It's typically caused by certain classes of medicines that block dopamine receptors in the brain. The typical offenders are a class of ...

SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that INGREZZA ® (valbenazine) capsules, the first FDA approved product indicated for the treatment ...